Ticagrelor vs Prasugrel for Acute Coronary Syndrome in Routine Care.

ABSTRACT:

Importance

In patients with acute coronary syndrome (ACS) undergoing invasive treatment, ticagrelor and prasugrel are guideline-recommended P2Y12 receptor inhibitors. The ISAR-REACT5 randomized clinical trial demonstrated superiority for prasugrel, although concerns were raised about the generalizability of some underpowered subgroup analyses.

Objectives

To emulate a randomized clinical trial evaluating the safety and effectiveness of ticagrelor vs prasugrel under the conditions of routine care in individuals with ACS planned to undergo an invasive treatment strategy.

Design, setting, and participants

This new-user cohort study included secondary data from a German statutory health insurance claims database between January 2012 and December 2021, using 1:1 propensity

SUBMITTER: Kruger N 

PROVIDER: S-EPMC11612834 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature